Meredith M Regan

Meredith M Regan

UNVERIFIED PROFILE

Are you Meredith M Regan?   Register this Author

Register author
Meredith M Regan

Meredith M Regan

Publications by authors named "Meredith M Regan"

Are you Meredith M Regan?   Register this Author

100Publications

3024Reads

36Profile Views

Reply to K.-D. Yu et al.

J Clin Oncol 2019 Jun 29;37(17):1516-1517. Epub 2019 Apr 29.

Thomas Ruhstaller, MD, Kantonsspital St Gallen, St Gallen, Universitatsspital Basel, Basel, and International Breast Cancer Study Group, Bern, Switzerland; and Meredith M. Regan, ScD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA and International Breast Cancer Study Group, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00325DOI Listing
June 2019

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.

J Clin Oncol 2019 Apr 27;37(11):862-866. Epub 2019 Feb 27.

5 Geneva University Hospitals, Lugano Viganello, Switzerland and Institute of Oncology of Southern Switzerland, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.02433
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455715PMC
April 2019

Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP.

Pract Radiat Oncol 2018 Nov - Dec;8(6):445-451. Epub 2018 Apr 14.

Harvard Medical School, Boston, Massachusetts; Beth Israel Deaconess Medical Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2018.04.007DOI Listing
January 2019

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

J Clin Oncol 2018 Sep 13:JCO1800242. Epub 2018 Sep 13.

Andrew D. Seidman, Memorial Sloan Kettering Cancer Center; Dawn L. Hershman, Columbia University, New York, NY; Louise Bordeleau, Hamilton Health Sciences and Canadian Cancer Trials Group, Hamilton, Ontario, Canada; Louis Fehrenbacher, Kaiser Permanente, Vallejo, CA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Jane Perlmutter, Gemini Group, Ann Arbor, MI; Lawrence Rubinstein, Jennifer Fallas Hayes, and Larissa A. Korde, National Cancer Institute; Lynn Pearson Butler, The Emmes Corporation, Rockville; Suparna B. Wedam, Julia A. Beaver, and Laleh Amiri-Kordestani, US Food and Drug Administration, Silver Spring; Jo Anne Zujewski, JZ Oncology, Bethesda, MD; Mary Lou Smith, Research Advocacy Network, Plano, TX; Meredith M. Regan, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Priya Rastogi, University of Pittsburgh Medical Center, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00242
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00242DOI Listing
September 2018

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

J Clin Oncol 2018 Jul 20;36(19):1941-1948. Epub 2018 Apr 20.

Mitch Dowsett and Andrew Dodson, Royal Marsden Hospital; Mitch Dowsett, Institute of Cancer Research; Ivana Sestak and Jack Cuzick, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; Meredith M. Regan, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA; Giuseppe Viale, University of Milan; Guiseppe Viale and Marco Colleoni, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital St Gallen, St Gallen, and International Breast Cancer Study Group and Swiss Group for Clinical Cancer Research, Berne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049399PMC
July 2018

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

N Engl J Med 2018 Jul 4;379(2):122-137. Epub 2018 Jun 4.

From the Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Newcastle, NSW (P.A.F.), and the University of Sydney, Sydney (A.S.C.) - all in Australia; the Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, Bellinzona (O.P.), Breast Cancer St. Gallen, St. Gallen (T.R.), and the International Breast Cancer Study Group Coordinating Center (R.M., M.R.-P., B.R., A.S.C.), University Hospital Inselspital (M.R.-P.), Bern - all in Switzerland; the University of Chicago Medical Center, Chicago (G.F.F.); the University of Calgary, Calgary, AB, Canada (B.A.W.); the Division of Medical Senology, European Institute of Oncology (M.C.), and the European Institute of Oncology and International Breast Cancer Study Group (A.G.), Milan, Ospedale Papa Giovanni XXIII, Bergamo (C.T.), Azienda Socio Sanitaria Territoriale Sette Laghi-Ospedale di Circolo and Fondazione Macchi, Varese (G.P.), Medical Oncology and Cancer Prevention, IRCCS, National Cancer Institute, Aviano (F.P., S.S.), the Department of Medicine, School of Medical Oncology, University of Udine, Udine (F.P.), Salvatore Maugeri Foundation, Pavia (L.P.), and the Hospital of Prato-Azienda Unità Sanitaria Locale Toscana Centro, Prato (A.D.L.) - all in Italy; the National Institute of Oncology, Budapest, Hungary (I.L.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.); University Hospital 12 de Octubre, Madrid (E.C.), Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (M.B.), and Instituto Valenciano de Oncologia, Valencia (M.A.C.) - all in Spain; the Susan F. Smith Center for Women's Cancers (H.J.B., E.P.W.) and the International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology (R.D.G., M.M.R.), Dana-Farber Cancer Institute, Harvard Medical School, the Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation (R.D.G.) - all in Boston; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France (H.R.B., M.D.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond (C.E.G.); Mayo Clinic, Rochester, MN (M.P.G., J.N.I.); Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (V.S.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (N.E.D.); Weston Park Hospital, Sheffield, United Kingdom (R.C.); and the Department of Obstetrics and Gynecology, University Medical Center, Regensburg, Germany (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457PMC
July 2018

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

J Clin Oncol 2018 04 14;36(11):1073-1079. Epub 2018 Feb 14.

Irene L. Wapnir, Stanford University School of Medicine, Stanford, CA; Karen N. Price and Shari Gelber, Frontier Science and Technology Research Foundation, Richard D. Gelber, Frontier Science and Technology Research Foundation, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Harvard Medical School, Meredith M. Regan, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Stewart J. Anderson, University of Pittsburgh Graduate School of Public Health; Priya Rastogi, University of Pittsburgh Cancer Institute; Norman Wolmark, Allegheny Health Network Cancer Institute, Pittsburgh, PA; André Robidoux, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec; Alexander H.G. Paterson, Tom Baker Cancer Centre, Calgary, Alberta, Canada; Miguel Martín, CIBERONC, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense, Madrid; José Manuel Baena-Cañada, Hospital Puerta del Mar, Cádiz, Spain; Johan W.R. Nortier, Leids Universitair Medisch Centrum, Leiden, Netherlands; Mothaffar F. Rimawi, Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St. Gallen; Stefan Aebi, Lucerne Cantonal Hospital and University of Bern, Switzerland; Eleftherios P. Mamounas, Orlando Health University of Florida Health Cancer Center, Orlando, FL; Charles E. Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; and Alan S. Coates, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891132PMC
April 2018

Reply to Y. Zhu et al.

J Clin Oncol 2018 02 21;36(5):515-516. Epub 2017 Dec 21.

Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.2872
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.2872DOI Listing
February 2018

Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al.

Qual Life Res 2018 01 5;27(1):149-152. Epub 2017 Sep 5.

International Breast Cancer Study Group Coordinating Center and Bern University Hospital, Inselspital, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-017-1695-1DOI Listing
January 2018

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

J Clin Oncol 2017 Sep 27;35(27):3113-3122. Epub 2017 Jun 27.

Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.0946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597253PMC
September 2017

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

J Clin Oncol 2017 09 10;35(27):3097-3104. Epub 2017 Aug 10.

Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer Institute, Boston, MA; Marc Buyse, International Drug Development Institute; Bertrand Tombal, Université Catholique de Louvain, Louvain-la-Neuve; Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor, Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation, Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA; Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, University College London, London, United Kingdom; James J. Dignam, University of Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France; Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652387PMC
September 2017

Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.

Cancer J 2017 Jan/Feb;23(1):63-67

From the *Beth Israel Deaconess Medical Center; †Dana-Farber Cancer Institute; and ‡Dana-Farber/Harvard Cancer Center, Boston; §Broad Institute of MIT and Harvard, Cambridge; and ∥Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000243DOI Listing
August 2017

Trial designs and results supporting treatment de-escalation and escalation.

Breast 2017 Aug 30;34 Suppl 1:S10-S12. Epub 2017 Jun 30.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.06.020DOI Listing
August 2017

Reply to L. Moscetti.

J Clin Oncol 2017 05 17;35(14):1628. Epub 2017 Jan 17.

Marco Colleoni, International Breast Cancer Study Group, Bern, Switzerland; and European Institute of Oncology, Milan, Italy; Kathryn P. Gray, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard T. H. Chen School of Public Health, Boston, MA; Richard D. Gelber, International Breast Cancer Study Group, Bern, Switzerland; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School; and Frontier Science and Technology Research Foundation, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Aron Goldhirsch, Breast Cancer, European Institute of Oncology, Milan, Italy; and International Breast Cancer Study Group, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5730DOI Listing
May 2017

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

J Clin Oncol 2017 Apr 13;35(11):1179-1188. Epub 2017 Feb 13.

Signe Borgquist and Judy E. Garber, Dana-Farber Cancer Institute, Harvard Medical School; Anita Giobbie-Hurder, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute; Richard D. Gelber, IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, T.H. Chan Harvard School of Public Health, and Frontier Science and Technology Research Foundation; Karen N. Price, IBCSG Statistical Center and Frontier Science and Technology Research Foundation; Meredith M. Regan, IBCSG Statistical Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; Signe Borgquist, Lund University, Lund, Sweden; Thomas P. Ahern, University of Vermont, Burlington, VT; Marco Colleoni and Aron Goldhirsch, IBCSG and European Institute of Oncology, Milan, Italy; István Láng, IBCSG and National Institute of Oncology, Budapest, Hungary; Marc Debled, Institut Bergonié, Bordeaux, France; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Roger von Moos, Cantonal Hospital Graubuenden, Chur; Swiss Group for Clinical Cancer Research and IBCSG; Manuela Rabaglio, IBCSG Coordinating Center and Inselspital, Bern; Beat Thürlimann, Breast Center St. Gallen, Kantonsspital, St. Gallen; Swiss Group for Clinical Cancer Research and IBCSG, Bern, Switzerland; Ian Smith, The Royal Marsden Hospital, London, United Kingdom; and Alan S. Coates, IBCSG and University of Sydney School of Public Health, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.3116DOI Listing
April 2017

Reply to F. Tomao et al.

J Clin Oncol 2016 12 30;34(34):4189-4190. Epub 2016 Sep 30.

Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477822PMC
December 2016

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

J Clin Oncol 2016 10 20;34(28):3400-8. Epub 2016 Jun 20.

Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.6595
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035120PMC
http://dx.doi.org/10.1200/JCO.2015.65.6595DOI Listing
October 2016

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clin Genitourin Cancer 2016 08 17;14(4):e299-305. Epub 2015 Dec 17.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.008DOI Listing
August 2016

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

J Clin Oncol 2016 07 4;34(19):2221-31. Epub 2016 Apr 4.

Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/03/31/JCO.2015.64
Web Search
http://dx.doi.org/10.1200/JCO.2015.64.3171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962708PMC
July 2016

Are SOFT and TEXT results practice changing and how?

Breast 2016 Jun 22;27:122-5. Epub 2016 Apr 22.

International Breast Cancer Study Group, Bern, Switzerland; Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Australia; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.02.008DOI Listing
June 2016

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

J Clin Oncol 2016 05 4;34(14):1584-93. Epub 2016 Jan 4.

Meritxell Bellet and Analía Azaro, Vall d'Hebron Institute of Oncology; Meritxell Bellet, Roser Ferrer, Roberto Catalán, and Analía Azaro, Vall d'Hebron University Hospital; Meritxell Bellet, Universitat Autònoma de Barcelona; Meritxell Bellet, Eva Ciruelos, Ana Lluch, Miguel Angel Climent, Gustavo Catalán, Antoni Avella, Uriel Bohn, Antonio González-Martin, Josefa Morales, and Josep Vázquez, SOLTI Group, Barcelona; Eva Ciruelos, University Hospital 12 de Octubre; Antonio González-Martin, MD Anderson Cancer Center Madrid, Madrid; Ana Lluch, Hospital Clinico Universitario de Valencia/Incliva Biomedical Research Institute; Miguel Angel Climent, Instituto Valenciano de Oncologia, Valencia; Gustavo Catalán, Hospital Son Llàtzer; Antoni Avella, Hospital Universitario Son Espases, Palma de Mallorca; Uriel Bohn, Hospital Dr Negrín de Gran Canaria, Canary Islands, Spain; Kathryn P. Gray and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray, Harvard T.H. Chan School of Public Health; Kathryn P. Gray, Karen N. Price, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Karen N. Price, Frontier Science and Technology Research Foundation; Meredith M. Regan, Harvard Medical School, Boston, MA; Agnita Rajasekaran, inVentiv Health Clinical Laboratory, Princeton, NJ; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, and International Breast Cancer Study Group, Melbourne, Victoria, Australia; and István Láng, National Institute of Oncology and International Breast Cancer Study Group, Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.2259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872316PMC
May 2016

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

J Clin Oncol 2016 05 28;34(14):1601-10. Epub 2016 Mar 28.

Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Brea

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872319PMC
May 2016

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

JAMA Oncol 2016 Feb;2(2):217-24

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium2Medical Oncology Clinic, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4377DOI Listing
February 2016

Predicting benefit of endocrine therapy for early breast cancer.

Authors:
Meredith M Regan

Breast 2015 Nov 5;24 Suppl 2:S129-31. Epub 2015 Aug 5.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641802PMC
November 2015

Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.

Mol Oncol 2015 Nov 29;9(9):1868-76. Epub 2015 Jul 29.

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Health System, Ann Arbor, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.07.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624024PMC
November 2015

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

J Clin Oncol 2015 Sep 27;33(25):2772-9. Epub 2015 Jul 27.

Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550691PMC
September 2015

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

J Immunother 2013 Nov-Dec;36(9):490-5

*Dartmouth Hitchcock Medical Center, Lebanon, NH †Dana-Farber Cancer Institute, Harvard School of Public Health ∥Beth Israel Deaconess Medical Center ‡‡Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ‡Vanderbilt University Medical Center, Nashville, TN §Loyola University Medical Center, Maywood, IL ¶Georgetown Lombardi Comprehensive Cancer Center, Washington, DC #St. Luke's Roosevelt Hospital Center, New York, NY **Earle A. Chiles Research Institute ††Providence Cancer Center, Portland, OR §§Department of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI ∥∥Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000003DOI Listing
June 2014

Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.

J Urol 2014 Mar 25;191(3):638-45. Epub 2013 Sep 25.

Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2013.09.040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006995PMC
March 2014

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

Breast 2013 Dec 2;22(6):1094-100. Epub 2013 Oct 2.

International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855346PMC
December 2013

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Future Oncol 2013 Oct;9(10):1477-87

'Sandro Pitigliani' Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.13.103DOI Listing
October 2013

Dramatic and prolonged PSA response after retreatment with a PSA vaccine.

Clin Genitourin Cancer 2013 Sep 20;11(3):362-4. Epub 2013 Jun 20.

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2013.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351423PMC
September 2013

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

J Natl Cancer Inst 2013 Sep 19;105(17):1332-4. Epub 2013 Aug 19.

Breast Oncology Program, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-5942, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888280PMC
September 2013

Challenges of guarantee-time bias.

J Clin Oncol 2013 Aug 8;31(23):2963-9. Epub 2013 Jul 8.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.5283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732313PMC
August 2013

SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.

J Biol Chem 2013 Mar 10;288(9):6478-87. Epub 2013 Jan 10.

Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M112.419184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585081PMC
March 2013

The effect of a controlled 8-week metabolic ward based lysine supplementation on muscle function, insulin sensitivity and leucine kinetics in young men.

Clin Nutr 2012 Dec 22;31(6):903-10. Epub 2012 Apr 22.

Division of Nutrition, St John's Research Institute, St John's National Academy of Health Sciences, Bangalore 560034, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clnu.2012.03.008DOI Listing
December 2012

Secondary hormonal therapy in men with castration-resistant prostate cancer.

Clin Genitourin Cancer 2011 Dec 29;9(2):95-103. Epub 2011 Sep 29.

Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney St., Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2011.06.006DOI Listing
December 2011

Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.

BJU Int 2011 Oct 16;108(7):1086-91. Epub 2011 Mar 16.

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2010.10037.xDOI Listing
October 2011

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Breast Cancer Res 2011 May 26;13(3):209. Epub 2011 May 26.

International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218925PMC
May 2011

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.

Cancer 2011 Feb 22;117(3):517-25. Epub 2010 Sep 22.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25394DOI Listing
February 2011

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

J Urol 2011 Feb 17;185(2):471-6. Epub 2010 Dec 17.

Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2010.09.115DOI Listing
February 2011

Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article.

J Neurosurg Spine 2010 Dec;13(6):789-94

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2010.6.SPINE10167DOI Listing
December 2010